US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
US4169888A
(en)
|
1977-10-17 |
1979-10-02 |
The Upjohn Company |
Composition of matter and process
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
EP0028683A1
(fr)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotique C-15003 PHO et sa préparation
|
US4364935A
(en)
|
1979-12-04 |
1982-12-21 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
|
WO1982001188A1
(fr)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
Composes 4,5-deoxymaytansinoide et leur procede de preparation
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US4970198A
(en)
|
1985-10-17 |
1990-11-13 |
American Cyanamid Company |
Antitumor antibiotics (LL-E33288 complex)
|
EP0206448B1
(fr)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hémoglobine liée à un poly(oxyde d'alkylène)
|
EP0272253A4
(fr)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
Procede pour ameliorer la stabilite des glycoproteines.
|
WO1987006265A1
(fr)
|
1986-04-17 |
1987-10-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5053394A
(en)
|
1988-09-21 |
1991-10-01 |
American Cyanamid Company |
Targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
FI102355B1
(fi)
|
1988-02-11 |
1998-11-30 |
Bristol Myers Squibb Co |
Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
|
US5084468A
(en)
|
1988-08-11 |
1992-01-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Dc-88a derivatives
|
JP2598116B2
(ja)
|
1988-12-28 |
1997-04-09 |
協和醗酵工業株式会社 |
新規物質dc113
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
JP2510335B2
(ja)
|
1989-07-03 |
1996-06-26 |
協和醗酵工業株式会社 |
Dc―88a誘導体
|
US5187186A
(en)
|
1989-07-03 |
1993-02-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Pyrroloindole derivatives
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(fr)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
JPH05507080A
(ja)
|
1990-05-03 |
1993-10-14 |
スクリップス クリニック アンド リサーチ ファウンデーション |
カリキアマイシン及びエスペラマイシンオリゴサッカライドの形成用中間体
|
US5968509A
(en)
|
1990-10-05 |
1999-10-19 |
Btp International Limited |
Antibodies with binding affinity for the CD3 antigen
|
CZ282603B6
(cs)
|
1991-03-06 |
1997-08-13 |
Merck Patent Gesellschaft Mit Beschränkter Haftun G |
Humanizované a chimerické monoklonální protilátky
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
WO1994004679A1
(fr)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Procede pour fabriquer des anticorps humanises
|
US5264586A
(en)
|
1991-07-17 |
1993-11-23 |
The Scripps Research Institute |
Analogs of calicheamicin gamma1I, method of making and using the same
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
ES2149768T3
(es)
|
1992-03-25 |
2000-11-16 |
Immunogen Inc |
Conjugados de agentes enlazantes de celulas derivados de cc-1065.
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
US6329507B1
(en)
|
1992-08-21 |
2001-12-11 |
The Dow Chemical Company |
Dimer and multimer forms of single chain polypeptides
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
AU690528B2
(en)
|
1992-12-04 |
1998-04-30 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
DE69327229T2
(de)
|
1992-12-11 |
2000-03-30 |
Dow Chemical Co |
Multivalente einkettige Antikörper
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
CA2125763C
(fr)
|
1993-07-02 |
2007-08-28 |
Maurice Kent Gately |
Homodimere p40 de l'interleukine-12
|
US5767237A
(en)
|
1993-10-01 |
1998-06-16 |
Teikoku Hormone Mfg. Co., Ltd. |
Peptide derivatives
|
GB9401182D0
(en)
|
1994-01-21 |
1994-03-16 |
Inst Of Cancer The Research |
Antibodies to EGF receptor and their antitumour effect
|
ATE271557T1
(de)
|
1994-04-22 |
2004-08-15 |
Kyowa Hakko Kogyo Kk |
Dc-89 derivat
|
JPH07309761A
(ja)
|
1994-05-20 |
1995-11-28 |
Kyowa Hakko Kogyo Co Ltd |
デュオカルマイシン誘導体の安定化法
|
US5945311A
(en)
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5550246A
(en)
|
1994-09-07 |
1996-08-27 |
The Scripps Research Institute |
Calicheamicin mimics
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
WO1996024369A1
(fr)
*
|
1995-02-06 |
1996-08-15 |
Genetics Institute, Inc. |
Formulations de preparation d'interleukine-12
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
JPH11507535A
(ja)
|
1995-06-07 |
1999-07-06 |
イムクローン システムズ インコーポレイテッド |
腫瘍の成長を抑制する抗体および抗体フラグメント類
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US7696338B2
(en)
|
1995-10-30 |
2010-04-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunotoxin fusion proteins and means for expression thereof
|
EP0871490B1
(fr)
|
1995-12-22 |
2003-03-19 |
Bristol-Myers Squibb Company |
Segments de liaison hydrazone ramifies
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック,インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
DK1037927T3
(da)
|
1997-12-08 |
2004-09-06 |
Emd Lexigen Res Ct Corp |
Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
|
ATE283364T1
(de)
|
1998-01-23 |
2004-12-15 |
Vlaams Interuniv Inst Biotech |
Mehrzweck-antikörperderivate
|
ES2340112T3
(es)
|
1998-04-20 |
2010-05-28 |
Glycart Biotechnology Ag |
Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
|
EP1071752B1
(fr)
|
1998-04-21 |
2003-07-09 |
Micromet AG |
Polypeptides specifiques a cd19 et cd3 et leurs utilisations
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
US7074405B1
(en)
|
1998-06-22 |
2006-07-11 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
ATE397457T1
(de)
|
1998-12-03 |
2008-06-15 |
Univ California |
Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
OA11917A
(en)
|
1998-12-23 |
2006-04-13 |
Abgenix Inc |
Human monoclonal antibodies to ctla-4.
|
US6723538B2
(en)
|
1999-03-11 |
2004-04-20 |
Micromet Ag |
Bispecific antibody and chemokine receptor constructs
|
EP1176195B1
(fr)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
|
US6939545B2
(en)
|
1999-04-28 |
2005-09-06 |
Genetics Institute, Llc |
Composition and method for treating inflammatory disorders
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
ATE316982T1
(de)
*
|
1999-08-09 |
2006-02-15 |
Lexigen Pharm Corp |
Mehrere zytokin-antikörper komplexen
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
CA2385528C
(fr)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
US6716410B1
(en)
|
1999-10-26 |
2004-04-06 |
The Regents Of The University Of California |
Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
|
DE60122286T2
(de)
|
2000-02-11 |
2007-08-02 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
US7129332B2
(en)
|
2000-02-25 |
2006-10-31 |
The United States Of America As Represented By The Department Of Health And Human Services |
Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
|
CN1281748C
(zh)
|
2000-03-15 |
2006-10-25 |
格纳西尼有限公司 |
为改善IL-12活性而突变的IL-12p40亚基基因及其作为DNA疫苗佐剂的用途
|
US20010035606A1
(en)
|
2000-03-28 |
2001-11-01 |
Schoen Alan H. |
Set of blocks for packing a cube
|
EP1278778A2
(fr)
|
2000-05-03 |
2003-01-29 |
Amgen Inc., |
Peptides modifies comprenant un domaine fc utilises comme agents therapeutiques
|
AU2001258567A1
(en)
|
2000-05-19 |
2001-11-26 |
Scancell Limited |
Humanised antibodies to the epidermal growth factor receptor
|
JP2004511430A
(ja)
|
2000-05-24 |
2004-04-15 |
イムクローン システムズ インコーポレイティド |
二重特異性免疫グロブリン様抗原結合蛋白および製造方法
|
BR0112111A
(pt)
|
2000-06-29 |
2003-05-06 |
Merck Patent Gmbh |
Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
|
AU2001283496A1
(en)
|
2000-07-25 |
2002-02-05 |
Immunomedics, Inc. |
Multivalent target binding protein
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
DE10043437A1
(de)
|
2000-09-04 |
2002-03-28 |
Horst Lindhofer |
Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
|
AU2001294175A1
(en)
|
2000-10-06 |
2002-04-22 |
Kyowa Hakko Kogyo Co. Ltd. |
Method of purifying antibody
|
PL218428B1
(pl)
|
2000-10-06 |
2014-12-31 |
Kyowa Hakko Kogyo Kk |
Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2002251913A1
(en)
|
2001-02-02 |
2002-08-19 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
MXPA03007323A
(es)
|
2001-02-19 |
2003-12-12 |
Merck Patent Gmbh |
Proteinas artificiales con inmunogenicidad reducida.
|
CA2440221C
(fr)
|
2001-03-07 |
2013-02-05 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Technique d'expression pour des proteines contenant un fragment d'anticorps isotype chimerique
|
EP1243276A1
(fr)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Prodrogues activables à séparateurs allongés et multiples
|
CA2442801A1
(fr)
|
2001-04-02 |
2002-10-10 |
Idec Pharmaceutical Corporation |
Anticorps recombinants co-exprimes avec gntiii
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
CN1463270A
(zh)
|
2001-05-31 |
2003-12-24 |
梅达莱克斯公司 |
细胞毒素、其有用的前体药物、连接基团和稳定剂
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
CN100497389C
(zh)
|
2001-06-13 |
2009-06-10 |
根马布股份公司 |
表皮生长因子受体(egfr)的人单克隆抗体
|
CA2452058A1
(fr)
|
2001-06-26 |
2003-01-09 |
Imclone Systems Incorporated |
Anticorps bispecifiques se liant aux recepteurs vegf
|
WO2003035835A2
(fr)
|
2001-10-25 |
2003-05-01 |
Genentech, Inc. |
Compositions de glycoproteine
|
US20080219974A1
(en)
|
2002-03-01 |
2008-09-11 |
Bernett Matthew J |
Optimized antibodies that target hm1.24
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
NZ554740A
(en)
|
2002-05-24 |
2009-01-31 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
ES2544527T3
(es)
|
2002-07-31 |
2015-09-01 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
EP1418184A1
(fr)
|
2002-11-08 |
2004-05-12 |
Cell Center Cologne GmbH |
Protéine recombinante comprenant les subunités p40 et p35 de IL-12 et un scFv et leur utilisation
|
AU2003282624A1
(en)
|
2002-11-14 |
2004-06-03 |
Syntarga B.V. |
Prodrugs built as multiple self-elimination-release spacers
|
UA90082C2
(ru)
|
2002-11-15 |
2010-04-12 |
Дженмаб А/С |
Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
|
CA2508660C
(fr)
|
2002-12-23 |
2013-08-20 |
Wyeth |
Anticorps anti pd-1 et utilisations
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
CN101186613B
(zh)
|
2003-05-20 |
2014-09-17 |
伊缪诺金公司 |
含有新的美登素类的改进的细胞毒剂
|
AU2004242846A1
(en)
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
|
NZ543202A
(en)
|
2003-05-31 |
2008-04-30 |
Micromet Ag |
Pharmaceutical composition comprising a bispecific antibody for epcam
|
US7888134B2
(en)
|
2003-06-05 |
2011-02-15 |
Oakland University |
Immunosensors: scFv-linker design for surface immobilization
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
US20050176028A1
(en)
|
2003-10-16 |
2005-08-11 |
Robert Hofmeister |
Deimmunized binding molecules to CD3
|
ZA200603619B
(en)
|
2003-11-06 |
2008-10-29 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
EP1701979A2
(fr)
|
2003-12-03 |
2006-09-20 |
Xencor, Inc. |
Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
|
WO2005056759A2
(fr)
|
2003-12-04 |
2005-06-23 |
Xencor, Inc. |
Procedes pour produire des proteines variantes presentant une plus grande concentration en chaine hote et compositions de celles-ci
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
NZ550934A
(en)
|
2004-05-19 |
2010-05-28 |
Medarex Inc |
Chemical linkers and conjugates thereof
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
EP1753783B1
(fr)
|
2004-06-03 |
2014-08-06 |
Novimmune SA |
Anticorps anti-cd3 et leurs methodes d'utilisation
|
WO2006004910A2
(fr)
|
2004-06-28 |
2006-01-12 |
Transtarget Inc. |
Anticorps bispecifiques ameliores
|
WO2006020258A2
(fr)
|
2004-07-17 |
2006-02-23 |
Imclone Systems Incorporated |
Nouveau anticorps bispecifique tetravalent
|
ZA200701783B
(en)
|
2004-09-02 |
2009-10-28 |
Genentech Inc |
Anti-Fc-gamma RIIB receptor antibody and uses therefor
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
AU2005289685B2
(en)
|
2004-09-24 |
2009-07-16 |
Amgen Inc. |
Modified Fc molecules
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8066989B2
(en)
|
2004-11-30 |
2011-11-29 |
Trion Pharma Gmbh |
Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
|
DE602006005200D1
(de)
|
2005-01-05 |
2009-04-02 |
F Star Biotech Forsch & Entw |
Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
|
JP4986633B2
(ja)
|
2005-01-12 |
2012-07-25 |
協和発酵キリン株式会社 |
安定化されたヒトIgG2およびIgG3抗体
|
ES2592271T3
(es)
|
2005-03-31 |
2016-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
EP1907592B1
(fr)
|
2005-07-01 |
2011-03-09 |
Dako Denmark A/S |
Molecules de liaison monomeriques et polymeriques utilisees dans la conjugaison de molecules biologiques et d'autres substances
|
US8309690B2
(en)
|
2005-07-01 |
2012-11-13 |
Medimmune, Llc |
Integrated approach for generating multidomain protein therapeutics
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
AU2006272597A1
(en)
|
2005-07-25 |
2007-02-01 |
Emergent Product Development Seattle Llc |
Single dose use of CD20-specific binding molecules
|
PL1912675T3
(pl)
|
2005-07-25 |
2014-10-31 |
Emergent Product Dev Seattle |
Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
|
JP2009509918A
(ja)
|
2005-08-05 |
2009-03-12 |
シンタルガ・ビーブイ |
トリアゾール含有放出可能なリンカー、これらの共役体、および製造方法
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20100209437A1
(en)
|
2005-09-12 |
2010-08-19 |
Greg Elson |
Anti-CD3 Antibody Fromulations
|
CA2624189A1
(fr)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Variants de fc dotes de proprietes de liaison aux recepteurs fc optimisees
|
ES2616316T3
(es)
|
2005-10-11 |
2017-06-12 |
Amgen Research (Munich) Gmbh |
Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos
|
KR20080073293A
(ko)
|
2005-10-14 |
2008-08-08 |
메디뮨 엘엘씨 |
항체 라이브러리의 세포 디스플레이
|
WO2007047829A2
(fr)
|
2005-10-19 |
2007-04-26 |
Laboratoires Serono S.A. |
Nouvelles protéines hétérodimères et utilisations de celles-ci
|
EP1777294A1
(fr)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
|
TW200732350A
(en)
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
WO2007059404A2
(fr)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Composes et conjugues cytotoxiques
|
US7820165B2
(en)
|
2005-11-21 |
2010-10-26 |
Merck Serono, S.A. |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
JP2009521474A
(ja)
|
2005-12-21 |
2009-06-04 |
メディミューン,エルエルシー |
EphA2BiTE分子およびその使用
|
JP5175214B2
(ja)
|
2005-12-30 |
2013-04-03 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
改良された安定性を有するインターロイキン−12p40変種
|
US7833754B2
(en)
|
2006-01-13 |
2010-11-16 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
IL-12 for expression in mammalian cell
|
NZ596494A
(en)
|
2006-01-13 |
2013-07-26 |
Us Gov Nat Inst Health |
Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
|
US8940784B2
(en)
|
2006-02-02 |
2015-01-27 |
Syntarga B.V. |
Water-soluble CC-1065 analogs and their conjugates
|
EP1820513A1
(fr)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
|
EP1829895A1
(fr)
|
2006-03-03 |
2007-09-05 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Molécule bispécifique anti-TLR9 et anti-CD32 contenant un épitope de lymphocyte T pour le traitement des allergies
|
GEP20135917B
(en)
|
2006-03-17 |
2013-09-10 |
Biogen Idec Inc |
Stabilized polypeptide compositions
|
ES2395969T3
(es)
|
2006-03-24 |
2013-02-18 |
Merck Patent Gmbh |
Dominios de proteínas heterodiméricas genéticamente modificados
|
EP4001409A1
(fr)
|
2006-03-31 |
2022-05-25 |
Chugai Seiyaku Kabushiki Kaisha |
Procédés pour le contrôle de la pharmacocinétique sanguine d'anticorps
|
WO2007114325A1
(fr)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé de modification d'anticorps pour purifier un anticorps bispécifique
|
WO2007113648A2
(fr)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Polythérapie à base d'un anticorps anti-ctla4
|
JP2009541275A
(ja)
|
2006-06-22 |
2009-11-26 |
ノボ・ノルデイスク・エー/エス |
二重特異性抗体の生産
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
WO2008042754A2
(fr)
|
2006-10-02 |
2008-04-10 |
Sea Lane Biotechnologies, Llc |
Conception et construction de diverses banques de peptides et de polypeptides synthétiques
|
CA2680237C
(fr)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructions et bibliotheques comprenant des sequences de chaines legeres de substitution d'anticorps
|
EP1975178A1
(fr)
|
2007-03-30 |
2008-10-01 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Anticorps modulaire transcytotique
|
WO2008119566A2
(fr)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Éléments de liaison bispécifiques spécifiques d'espèces croisées
|
PT2520590T
(pt)
|
2007-04-03 |
2018-11-14 |
Amgen Res Munich Gmbh |
Domínio de ligação específico de espécies cruzadas
|
WO2008124858A2
(fr)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Récepteur ciblé
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
EP1987839A1
(fr)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
|
EP3293266A1
(fr)
|
2007-05-04 |
2018-03-14 |
University Health Network |
Immunothérapie par il-12 pour le cancer
|
NZ581395A
(en)
|
2007-05-14 |
2012-08-31 |
Biogen Idec Inc |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
DK2176298T3
(en)
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
US20100267934A1
(en)
|
2007-05-31 |
2010-10-21 |
Genmab A/S |
Stable igg4 antibodies
|
CA2691322A1
(fr)
|
2007-06-12 |
2008-12-24 |
Wyeth |
Compositions therapeutiques anti-cd20 et procedes correspondants
|
CA2855098C
(fr)
|
2007-06-18 |
2018-02-27 |
Merck Sharp & Dohme B.V. |
Anticorps diriges contre le recepteur humain de mort programmee pd-1
|
CN101802006B
(zh)
|
2007-06-26 |
2013-08-14 |
F-星生物技术研究与开发有限公司 |
展示结合剂
|
AU2007357156B2
(en)
|
2007-08-01 |
2013-01-10 |
Syntarga B.V. |
Substituted CC-1065 analogs and their conjugates
|
CA2695382A1
(fr)
|
2007-08-01 |
2009-02-05 |
The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of |
Immunotoxine de la toxine diphterique d'un dianticorps de repliement et ses procedes d'utilisation
|
CN101842116A
(zh)
|
2007-08-28 |
2010-09-22 |
比奥根艾迪克Ma公司 |
结合igf-1r多个表位的组合物
|
EP2033657A1
(fr)
|
2007-09-04 |
2009-03-11 |
Trion Pharma Gmbh |
Application d'anticorps intra-opératoire trifonctionnelle pour la prophylaxie de la dissémination des cellules cancérigènes intrapéritonéales
|
JP5963341B2
(ja)
|
2007-09-14 |
2016-08-10 |
アムジエン・インコーポレーテツド |
均質な抗体集団
|
MX342551B
(es)
|
2007-09-26 |
2016-10-04 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo modificada.
|
EP2195341B1
(fr)
|
2007-09-26 |
2017-03-22 |
UCB Biopharma SPRL |
Fusions d'anticorps à double spécificité
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
EP4098661A1
(fr)
|
2007-12-26 |
2022-12-07 |
Xencor, Inc. |
Variantes fc avec liaison altérée en fcrn
|
ES2774337T3
(es)
|
2008-01-07 |
2020-07-20 |
Amgen Inc |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
WO2009106096A1
(fr)
|
2008-02-27 |
2009-09-03 |
Fresenius Biotech Gmbh |
Traitement de tumeurs résistantes par des anticorps trifonctionnels
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
WO2009126944A1
(fr)
|
2008-04-11 |
2009-10-15 |
Trubion Pharmaceuticals, Inc. |
Produits d’immunothérapie de cd37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
|
WO2009129538A2
(fr)
|
2008-04-18 |
2009-10-22 |
Xencor, Inc. |
Anticorps monoclonaux d’équivalent humain conçus à partir de régions variables non humaines
|
JP5624535B2
(ja)
|
2008-05-02 |
2014-11-12 |
シアトル ジェネティクス,インコーポレーテッド |
低いコアフコシル化を有する抗体及び抗体誘導体を調製するための方法並びに組成物
|
RU2010153580A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
DK2350129T3
(en)
|
2008-08-25 |
2015-08-31 |
Amplimmune Inc |
PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF
|
KR20110074850A
(ko)
|
2008-08-25 |
2011-07-04 |
앰플리뮨, 인크. |
Pd-1 길항제 및 그의 사용 방법
|
WO2010028796A1
(fr)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Anticorps hexavalents trispécifiques
|
US20170247470A9
(en)
|
2008-09-17 |
2017-08-31 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
EP2796469B1
(fr)
|
2008-09-17 |
2019-05-08 |
Xencor, Inc. |
Nouvelles compositions et méthodes de traitement de troubles induits par IgE
|
MX2011003133A
(es)
|
2008-09-26 |
2011-04-21 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-egfr/anti-igf-1r.
|
NZ591134A
(en)
|
2008-10-01 |
2012-08-31 |
Micromet Ag |
Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa)
|
NZ591087A
(en)
|
2008-10-01 |
2012-08-31 |
Micromet Ag |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
US10981998B2
(en)
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
PT2352763E
(pt)
|
2008-10-01 |
2016-06-02 |
Amgen Res (Munich) Gmbh |
Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular
|
EA032828B1
(ru)
|
2008-10-10 |
2019-07-31 |
Аптево Рисёрч Энд Девелопмент Ллс |
Иммунотерапевтические средства против комплекса tcr
|
CN102317283A
(zh)
|
2008-11-03 |
2012-01-11 |
辛塔佳股份有限公司 |
新型cc-1065类似物及其缀合物
|
SG10201708690SA
(en)
|
2008-12-09 |
2017-12-28 |
Genentech Inc |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
EP2389192A4
(fr)
|
2009-01-23 |
2013-01-16 |
Biogen Idec Inc |
Polypeptides fc stabilisés avec une fonction effectrice réduite et procédés d'utilisation
|
CA2754528A1
(fr)
|
2009-03-06 |
2010-09-10 |
Genetech, Inc. |
Formulation d'anticorps
|
EP2233500A1
(fr)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Variantes Fc optimisées
|
AU2010230563A1
(en)
|
2009-04-02 |
2011-09-22 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain Fab fragments
|
EP2417159A1
(fr)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Anticorps anti-erbb-3/anti-c-met bispécifiques
|
BRPI1014449A2
(pt)
|
2009-04-07 |
2017-06-27 |
Roche Glycart Ag |
anticorpos biespecíficos anti-erbb-2/ anti-c-met.
|
US20100256340A1
(en)
|
2009-04-07 |
2010-10-07 |
Ulrich Brinkmann |
Trivalent, bispecific antibodies
|
EP2241576A1
(fr)
|
2009-04-17 |
2010-10-20 |
Trion Pharma Gmbh |
Utilisation des anticorps bispécifiques trifonctionnels pour le traitement des tumeurs associées aux cellules souches de cancer CD133+/EpCAM+
|
MX2011011925A
(es)
|
2009-05-27 |
2011-12-06 |
Hoffmann La Roche |
Anticuerpos triespecificos o tetraespecificos.
|
TWI560271B
(en)
|
2009-06-26 |
2016-12-01 |
Sealane Biotechnologies Llc |
Expression of surrogate light chains
|
CN102471378B
(zh)
|
2009-06-26 |
2014-04-02 |
瑞泽恩制药公司 |
容易地分离的具有天然免疫球蛋白形式的双特异性抗体
|
EP2451840B1
(fr)
|
2009-07-08 |
2018-12-26 |
Amgen Inc. |
Conception de molécules fc d'anticorps exemptes d'agrégation et stables par ingénierie de l'interface du domaine ch3
|
WO2011028952A1
(fr)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
|
DE102009045006A1
(de)
|
2009-09-25 |
2011-04-14 |
Technische Universität Dresden |
Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
|
SG179204A1
(en)
|
2009-10-27 |
2012-04-27 |
Micromet Ag |
Dosage regimen for administering a cd19xcd3 bispecific antibody
|
JP2013511281A
(ja)
|
2009-11-23 |
2013-04-04 |
アムジェン インコーポレイテッド |
単量体抗体Fc
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
CA2782218C
(fr)
|
2009-11-30 |
2018-07-31 |
Janssen Biotech, Inc. |
Mutants du fc des anticorps presentant une ablation des fonctions effectrices
|
PL2522724T3
(pl)
|
2009-12-25 |
2020-07-13 |
Chugai Seiyaku Kabushiki Kaisha |
Sposób modyfikowania polipetydów do oczyszczania multimerów polipeptydowych
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
CN105693861A
(zh)
|
2009-12-29 |
2016-06-22 |
新兴产品开发西雅图有限公司 |
异二聚体结合蛋白及其应用
|
US8557013B2
(en)
|
2009-12-30 |
2013-10-15 |
Vitag Holdings, Llc |
Bioorganically-augmented high value fertilizer
|
US20110189178A1
(en)
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
CA2794745A1
(fr)
|
2010-03-29 |
2011-10-06 |
Zymeworks, Inc. |
Anticorps presentant une fonction effectrice amelioree ou supprimee
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
AU2011244282A1
(en)
|
2010-04-20 |
2012-11-15 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
WO2011143545A1
(fr)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Protéines hétérodimériques et leurs procédés de production et de purification
|
DK2580243T3
(da)
|
2010-06-09 |
2020-01-13 |
Genmab As |
Antibodies against human cd38
|
TWI629483B
(zh)
|
2010-06-11 |
2018-07-11 |
協和醱酵麒麟有限公司 |
anti-TIM-3 antibody
|
CA2802344C
(fr)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques
|
EP3029066B1
(fr)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Anticorps à points isoélectriques modifiés
|
EP2601216B1
(fr)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Di-anticorps covalents et utilisations associées
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
WO2012032080A1
(fr)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Fc humain stabilisé
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
HUE032782T2
(en)
|
2010-11-10 |
2017-10-30 |
Amgen Res (Munich) Gmbh |
Prevention of side effects caused by CD3-specific binding domains
|
CN103282385A
(zh)
|
2010-11-12 |
2013-09-04 |
美国洛克菲勒大学 |
用于hiv治疗的融合蛋白
|
LT3489255T
(lt)
|
2011-02-10 |
2021-08-25 |
Roche Glycart Ag |
Mutantiniai interleukino-2 polipeptidai
|
EP2681245B1
(fr)
|
2011-03-03 |
2018-05-09 |
Zymeworks Inc. |
Conception et constructions d'échafaudage hétéromultimère multivalent
|
AU2012229251A1
(en)
|
2011-03-11 |
2013-09-12 |
Amgen Inc. |
Method of correlated mutational analysis to improve therapeutic antibodies
|
US20140112926A1
(en)
|
2011-03-16 |
2014-04-24 |
Amgen Inc. |
Fc VARIANTS
|
NZ608724A
(en)
|
2011-03-25 |
2015-12-24 |
Glenmark Pharmaceuticals Sa |
Hetero-dimeric immunoglobulins
|
TWI743461B
(zh)
|
2011-03-28 |
2021-10-21 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
MX354359B
(es)
|
2011-03-29 |
2018-02-28 |
Roche Glycart Ag |
Variantes de fragmento cristalizable (fc) de los anticuerpos.
|
EP3753572A1
(fr)
|
2011-04-28 |
2020-12-23 |
Amgen Research (Munich) GmbH |
Régime posologique pour l'administration d'un anticorps bispécifique cd19xcd3 à des patients à risque d'éventuels effets indésirables
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
EP2714733B1
(fr)
|
2011-05-21 |
2019-01-23 |
MacroGenics, Inc. |
Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
|
CA2834589A1
(fr)
|
2011-05-25 |
2012-11-29 |
Merck Sharp & Dohme Corp. |
Procede de preparation de polypeptides contenant fc a proprietes ameliorees
|
WO2013006544A1
(fr)
|
2011-07-06 |
2013-01-10 |
Medimmune, Llc |
Procédé de préparation de polypeptides multimères
|
EP2736928B1
(fr)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Proteines "sur"-liantes dirigees contre erbb3
|
WO2013022855A1
(fr)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Anticorps avec points isoélectriques modifiés et immunofiltration
|
UA116192C2
(uk)
|
2011-08-23 |
2018-02-26 |
Рош Глікарт Аг |
Активуюча т-клітини біоспецифічна антигензв'язуюча молекула
|
EP2748197A2
(fr)
|
2011-08-26 |
2014-07-02 |
Merrimack Pharmaceuticals, Inc. |
Anticorps bispécifiques à fc en tandem
|
WO2013047748A1
(fr)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
|
DK2766392T3
(da)
|
2011-10-10 |
2019-10-07 |
Xencor Inc |
Fremgangsmåde til oprensning af antistoffer
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
ES2888249T3
(es)
|
2011-10-11 |
2022-01-03 |
Univ Zuerich |
Medicamento de combinación que comprende IL-12 y un agente para el bloqueo de moléculas inhibidoras de linfocitos T para terapia tumoral
|
WO2013056851A2
(fr)
|
2011-10-20 |
2013-04-25 |
Esbatech - A Novartis Company Llc |
Anticorps stable se liant à de multiples antigènes
|
CN104011207B
(zh)
|
2011-10-31 |
2018-09-18 |
中外制药株式会社 |
控制了重链与轻链的缔合的抗原结合分子
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Fc 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
SG11201402603WA
(en)
|
2011-11-28 |
2014-06-27 |
Merck Patent Gmbh |
Anti-pd-l1 antibodies and uses thereof
|
KR102101819B1
(ko)
|
2011-12-12 |
2020-04-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
|
WO2013096828A1
(fr)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Protéines substitutives de liaison
|
SG10201805584YA
(en)
|
2012-02-24 |
2018-08-30 |
Chugai Pharmaceutical Co Ltd |
ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
|
EA035344B1
(ru)
|
2012-04-20 |
2020-05-29 |
Мерюс Н.В. |
Способ получения двух антител из одной клетки-хозяина
|
DK3489254T3
(da)
|
2012-04-30 |
2022-11-07 |
Biocon Ltd |
Målrettede/immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf
|
US20150353630A1
(en)
|
2012-05-30 |
2015-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
US20140154253A1
(en)
|
2012-07-13 |
2014-06-05 |
Zymeworks Inc. |
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
|
IN2015DN01299A
(fr)
|
2012-07-23 |
2015-07-03 |
Zymeworks Inc |
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
EP2904016B1
(fr)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Anticorps exempts de fc comprenant deux fragments fab et procédés d'utilisation
|
CA2892059C
(fr)
|
2012-11-21 |
2023-02-14 |
Wuhan Yzy Biopharma Co., Ltd. |
Anticorps bispecifiques
|
US20140377269A1
(en)
|
2012-12-19 |
2014-12-25 |
Adimab, Llc |
Multivalent antibody analogs, and methods of their preparation and use
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
CA3211863A1
(fr)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Nouvelles proteines heterodimeres
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014207549B2
(en)
|
2013-01-15 |
2018-12-06 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN113045660B
(zh)
|
2013-03-13 |
2023-09-01 |
伊麦吉纳博公司 |
与cd8的抗原结合构建体
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
KR102561553B1
(ko)
|
2013-03-15 |
2023-07-31 |
젠코어 인코포레이티드 |
이형이량체 단백질
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
JP6329343B2
(ja)
|
2013-06-13 |
2018-05-23 |
任天堂株式会社 |
画像処理システム、画像処理装置、画像処理プログラム、および画像処理方法
|
WO2014209804A1
(fr)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Anticorps bispécifiques
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
EP4269441A3
(fr)
|
2013-08-08 |
2024-01-24 |
Cytune Pharma |
Domaine sushi de l'il-15 et de l'il-15ralpha basé sur des modulokines
|
EP2839842A1
(fr)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
|
EP3066133A1
(fr)
|
2013-11-04 |
2016-09-14 |
Glenmark Pharmaceuticals S.A. |
Production de cellules t reciblant des immunoglobulines héréro-dimériques
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
WO2015095249A1
(fr)
|
2013-12-18 |
2015-06-25 |
Intrexon Corporation |
Acides nucléiques d'il-12 monocaténaires, polypeptides d'il-12 monocaténaires, et leurs utilisations
|
US10519251B2
(en)
|
2013-12-30 |
2019-12-31 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
CN105189562B
(zh)
|
2014-01-08 |
2019-08-16 |
上海恒瑞医药有限公司 |
Il-15异源二聚体蛋白及其用途
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
KR20220126813A
(ko)
|
2014-03-14 |
2022-09-16 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
AU2015237184B2
(en)
|
2014-03-28 |
2020-11-26 |
Xencor, Inc. |
Bispecific antibodies that bind to CD38 and CD3
|
EP3137105A4
(fr)
|
2014-04-30 |
2017-12-27 |
President and Fellows of Harvard College |
Dispositifs de vaccin combiné et procédés de destruction de cellules cancéreuses
|
SG10201913680PA
(en)
|
2014-05-29 |
2020-03-30 |
Macrogenics Inc |
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
|
AU2015289621A1
(en)
|
2014-07-16 |
2017-01-12 |
Genentech, Inc. |
Methods of treating cancer using TIGIT inhibitors and anti-cancer agents
|
WO2016014984A1
(fr)
|
2014-07-24 |
2016-01-28 |
Xencor, Inc. |
Élimination rapide de complexes antigéniques à l'aide de nouveaux anticorps
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
SG11201702295UA
(en)
|
2014-09-22 |
2017-04-27 |
Intrexon Corp |
Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
BR112017008666A2
(pt)
|
2014-11-05 |
2018-01-30 |
Genentech, Inc. |
anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
|
SI3789402T1
(sl)
|
2014-11-20 |
2022-10-28 |
F. Hoffmann-La Roche Ag |
Kombinirano zdravljenje z bispecifičnimi molekulami, ki vežejo antigen in aktivirajo celice T, ter antagonisti za vezavo osi PD-1
|
TN2017000222A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
US20160176969A1
(en)
|
2014-11-26 |
2016-06-23 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
CU24597B1
(es)
|
2014-11-26 |
2022-05-11 |
Xencor Inc |
Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
KR102644115B1
(ko)
|
2014-12-23 |
2024-03-05 |
브리스톨-마이어스 스큅 컴퍼니 |
Tigit에 대한 항체
|
DK3242890T3
(da)
|
2015-01-08 |
2019-10-21 |
BioNTech SE |
Agonistiske tnf-receptor-bindingsmidler
|
BR112017015136A2
(pt)
|
2015-01-14 |
2018-01-30 |
Compass Therapeutics Llc |
polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
EP4059514A1
(fr)
|
2015-05-08 |
2022-09-21 |
Xencor, Inc. |
Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Tigit結合劑和彼之用途
|
KR20180093127A
(ko)
|
2015-07-30 |
2018-08-20 |
마크로제닉스, 인크. |
Pd-1-결합 분자 및 그것의 사용 방법
|
CN106520778A
(zh)
|
2015-09-09 |
2017-03-22 |
北京锤特生物科技有限公司 |
改造的白介素12及其在制备治疗肿瘤的药物中的用途
|
RU2732591C2
(ru)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Анти-tigit антитела и способы применения
|
CA3001590A1
(fr)
|
2015-10-10 |
2017-04-13 |
Intrexon Corporation |
Controle therapeutique ameliore de formes d'interleukine-12 destabilisees sensibles a la proteolyse
|
CA3007030A1
(fr)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Anticorps heterodimees se liant a cd3 et psma
|
EA201891428A1
(ru)
|
2015-12-22 |
2018-12-28 |
Регенерон Фармасьютикалз, Инк. |
Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
|
US10344067B2
(en)
|
2016-02-25 |
2019-07-09 |
Deutsches Krebsforschungszentrum |
RNA viruses expressing IL-12 for immunovirotherapy
|
US20170349657A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
WO2017210443A1
(fr)
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Anticorps bispécifiques qui lient cd123 et cd3
|
EP3252078A1
(fr)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Anticorps de type ii contre cd20 et anticorps bispecifique contre cd20/cd3 pour traitement de cancer
|
BR112018075198A2
(pt)
|
2016-06-07 |
2019-03-19 |
Macrogenics, Inc. |
método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit
|
WO2017218707A2
(fr)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Anticorps inhibiteurs de points de contrôle bispécifiques
|
WO2018030806A1
(fr)
*
|
2016-08-10 |
2018-02-15 |
아주대학교산학협력단 |
Cytokine fusionnée à un hétérodimère fc d'immunoglobuline et composition pharmaceutique la contenant
|
US10696722B2
(en)
*
|
2016-08-10 |
2020-06-30 |
Ajou University Industry-Academic Cooperation Foundation |
Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
|
MX2019002328A
(es)
|
2016-08-29 |
2019-07-04 |
Psioxus Therapeutics Ltd |
Adenovirus armado con captador biespecífico de linfocitos t (bite).
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
JP2019532648A
(ja)
|
2016-10-07 |
2019-11-14 |
ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム |
がんの治療のための膜係留il−12を発現しているt細胞
|
JP7142630B2
(ja)
|
2016-10-14 |
2022-09-27 |
ゼンコア インコーポレイテッド |
IL15/IL15Rαヘテロ二量体FC-融合タンパク質
|
CA3063723A1
(fr)
|
2017-05-18 |
2018-11-22 |
Modernatx, Inc. |
Polynucleotides codant pour des polypeptides d'interleukine-12 (il12) ancres et leurs utilisations
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
US20210061911A1
(en)
|
2017-09-07 |
2021-03-04 |
Macrogenics, Inc. |
Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2019129053A1
(fr)
|
2017-12-26 |
2019-07-04 |
南京金斯瑞生物科技有限公司 |
Protéine de fusion dimère utilisant une région fc d'anticorps en tant que squelette et utilisation associée
|
CN113195523A
(zh)
|
2018-10-03 |
2021-07-30 |
Xencor股份有限公司 |
IL-12异源二聚体Fc融合蛋白
|
PE20211279A1
(es)
|
2018-10-23 |
2021-07-19 |
Dragonfly Therapeutics Inc |
Proteinas heterodimericas fusionadas con fc
|